BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls
- PMID: 30078507
- DOI: 10.1016/j.ygyno.2018.07.024
BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls
Abstract
Objective: To investigate the BRCA status in Chinese patients with ovarian cancer (OC). Though there were two large prevalence studies in Chinese OC patients, this was the first time to observe it in healthy controls.
Methods: We performed BRCA mutation screening using next-generation sequencing to determine the prevalence of BRCA germline deleterious mutations in an unselected cohort of Chinese OC patients (n = 1331) versus healthy controls (n = 1763) and describe the types and spectrum of BRCA deleterious variants.
Results: Among the 1331 patients with OC, 227 (17.1%) carried deleterious variants in BRCA1 and 70 (5.3%) carried deleterious variants in BRCA2. Of 1763 control subjects, 6 (0.3%) and 2 (0.1%) had deleterious variants in BRCA1 and BRCA2. No patient carried mutations in both BRCA1 and BRCA2 simultaneously. Sixty-three novel mutations were identified, and three Chinese specific hot-spot mutations were notified as BRCA1 c.5470_5477delATTGGGCA, BRCA1 c.981_982delAT, and BRCA1 c.3770_3771delAG. Interestingly, all these high-frequency recurrent mutations were distributed on exon 10, which may also be the Chinese OC BRCA mutations' distinct characteristics. In addition, in our study, the estimated odds ratio (OR) of OC associated with BRCA1 positive variants were approximately 34.6 (95% CI, 12.5-95.7) in age group under 40 and 42.4 (95% CI, 5.9-305.2) in group older than 50 in the Chinese population, respectively.
Conclusions: We recommend BRCA testing to all Chinese OC patients and those general Chinese who have family members with hereditary breast and ovarian related cancer (HBOC)-related cancers. Variants carriers would not only benefit from early prevention of OC but also for the medical management.
Keywords: BRCA gene; Case-control studies; Chinese genetic testing; Exon mutation; High-throughput nucleotide sequencing; Ovarian neoplasms.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Prevalence and spectrum of BRCA germline variants in mainland Chinese familial breast and ovarian cancer patients.Oncotarget. 2016 Feb 23;7(8):9600-12. doi: 10.18632/oncotarget.7144. Oncotarget. 2016. PMID: 26848529 Free PMC article.
-
High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.Breast Cancer Res Treat. 2018 Apr;168(3):695-702. doi: 10.1007/s10549-017-4635-4. Epub 2018 Jan 2. Breast Cancer Res Treat. 2018. PMID: 29297111
-
Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia.J Transl Med. 2021 Mar 16;19(1):108. doi: 10.1186/s12967-021-02772-y. J Transl Med. 2021. PMID: 33726785 Free PMC article.
-
BRCA mutations: Implications of genetic testing in ovarian cancer.Indian J Cancer. 2022 Mar;59(Supplement):S56-S67. doi: 10.4103/ijc.IJC_1394_20. Indian J Cancer. 2022. PMID: 35343191 Review.
-
Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI - Current Developments for the Classification of Variants.Klin Onkol. 2019 Summer;32(Supplementum2):51-71. doi: 10.14735/amko2019S51. Klin Onkol. 2019. PMID: 31409081 Review. English.
Cited by
-
Differences in Ovarian and Other Cancers Risks by Population and BRCA Mutation Location.Genes (Basel). 2021 Jul 8;12(7):1050. doi: 10.3390/genes12071050. Genes (Basel). 2021. PMID: 34356066 Free PMC article. Review.
-
Assessing the Variations in Breast/Ovarian Cancer Risk for Chinese BRCA1/2 Carriers.J Oncol. 2022 Mar 26;2022:9390539. doi: 10.1155/2022/9390539. eCollection 2022. J Oncol. 2022. PMID: 35378767 Free PMC article.
-
Thai patients who fulfilled NCCN criteria for breast/ovarian cancer genetic assessment demonstrated high prevalence of germline mutations in cancer susceptibility genes: implication to Asian population testing.Breast Cancer Res Treat. 2021 Jul;188(1):237-248. doi: 10.1007/s10549-021-06152-4. Epub 2021 Mar 1. Breast Cancer Res Treat. 2021. PMID: 33649982 Free PMC article.
-
Overview on population screening for carriers with germline BRCA mutation in China.Front Oncol. 2022 Nov 9;12:1002360. doi: 10.3389/fonc.2022.1002360. eCollection 2022. Front Oncol. 2022. PMID: 36439508 Free PMC article. Review.
-
East Asian Gynecologic Oncology Trial Group (EAGOT): founding history and future perspective.J Gynecol Oncol. 2023 Sep;34(5):e86. doi: 10.3802/jgo.2023.34.e86. Epub 2023 Aug 4. J Gynecol Oncol. 2023. PMID: 37593814 Free PMC article. Review.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous